IMPAACT Studies in Development
The study you are looking for is in protocol development.
As the study protocol reaches Version 1.0, a study page will be developed.
|
Study Number (DAIDS ID) |
Study Title | Status |
|---|---|---|
|
IMPAACT 2014 (34150) |
Phase I/II Trial of the Pharmacokinetics, Safety, Tolerability and Efficacy of MK-1439 (Doravirine or DOR) and MK-1439A (FDC of DOR + lamivudine + TDF) in HIV-infected Adolescents |
In Development |
|
IMPAACT 2015 (TBD) |
Evaluation of the HIV Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Neurocognitive Impairment |
In Development |
|
IMPAACT 2013 (30074) |
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV/NS2/N/delta M2-2-HindIII, Lot RSV#011A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age |
In Development |
|
IMPAACT 2010 (30129) |
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants |
In Development |
|
IMPAACT 2009 (30020) |
Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women |
In Development |
|
IMPAACT 2003B (12041) |
(Phoenix) Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients |
In Development |
|
IMPAACT 2008 (20735) |
Phase I/II Multisite Randomized Controlled Study of Monoclonal Antibody VRC01 Combined with Antiretroviral Therapy to Promote Clearance of HIV-1 Infected Cells in Infants |
In Development |
|
IMPAACT 2006 (12069) |
NextGen Strategy Trial: A Phase II, Randomized Study Assessing Lopinavir/Ritonavir- and Dolutegravir-Based Antiretroviral Treatment in Infants and Children >= 1 Month to < 3 Years of Age |
In Development |
|
IMPAACT 2005 (20721) |
A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB |
In Development |
|
IMPAACT 2004 (12050) |
Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in South African Breastfeeding Infants |
In Development |